Results 141 to 150 of about 278,920 (292)

Construction of a MOF‐Based Snap‐Top Delivery Nanosystem for Powerful Dual‐Responsive Synergistic Colitis Treatment

open access: yesAdvanced Science, EarlyView.
A snap‐top delivery nanosystem based on an azobenzene metal–organic framework achieves targeted release of 6‐mercaptopurine via acid‐stable frameworks and hypoxia/pH dual‐responsive β‐cyclodextrin gates. This multifunctional platform integrates three synergistic mechanisms: precision drug delivery to inflammatory sites, intrinsic antioxidant properties
Xin Li   +6 more
wiley   +1 more source

Laparoscopic Delivery of a MnO2‐P‐ICG Patch for Photodynamic Therapy and NK Cell‐Driven Immunotherapy in Hepatocellular Carcinoma

open access: yesAdvanced Science, EarlyView.
This study proposes a flexible MnO2‐P‐ICG nanofiber patch for laparoscopic treatment of liver tumors. The patch alleviates tumor hypoxia and induces photodynamic therapy (PDT) triggered immunogenic cell death, thereby activating the cGAS‐STING pathway and, in synergy with pachymaran, promoting NK cell–mediated innate immunity. This synergistic strategy
Jie Lin   +14 more
wiley   +1 more source

Senomorphic Small Extracellular Vesicles Delivered by a Tissue‐Adhesive α‐Lipoic‐Acid Hydrogel Enable Immuno‐Rejuvenation for Bone‐Tendon Interface Regeneration

open access: yesAdvanced Science, EarlyView.
This work identifies M1 macrophage‐mediated inflammation as a key driver of BMSC senescence and bone microstructural deterioration at the enthesis. A tissue‐adhesive hydrogel delivering senomorphic small extracellular vesicles suppresses this inflammatory‐senescent cascade and enhances BMSC resilience by inhibiting the cGAS‐STING‐NF‐κB pathway.
Lingzhi Kong   +8 more
wiley   +1 more source

Interferon-gamma release assay positivity in populations at high risk of TB infection. [PDF]

open access: yesIJTLD Open
Dagnew AF   +22 more
europepmc   +1 more source

scResponse: A Rank‐Based Method for Identifying Cell States That Contribute to Immunotherapy Response by Single‐Cell Data

open access: yesAdvanced Science, EarlyView.
Although the tumor microenvironment is known to shape immunotherapy response, its key determinants remain elusive, underscoring the critical need for single‐cell resolution analytical frameworks. We present scResponse, an efficient algorithm to quantify single‐cell responses to immunotherapy. By capturing diverse cellular subtypes and states associated
Qi Dong   +21 more
wiley   +1 more source

Smartly Assembled near‐Micron RF‐Responsive Agents Bridge Transarterial Embolization and Immunothermal Potentiation

open access: yesAdvanced Science, EarlyView.
ABSTRACT Hepatocellular carcinoma (HCC) remains a significant clinical challenge due to the limited efficacy of conventional treatments like surgery, radiofrequency ablation (RFA), and transarterial embolization (TAE). Here, we develop an innovative TAE and immunothermal therapy strategy based on smartly assembled near‐micron layered double hydroxide ...
Qitao Hu   +12 more
wiley   +1 more source

Rational Design of Broad‐Spectrum Anti‐Enteroviral Molecular Glues Targeting Enteroviral RNAi Suppressors

open access: yesAdvanced Science, EarlyView.
By leveraging this homodimerization mechanism, molecular glues were rationally designed to induce dysfunctional 3A dimerization, thereby restoring antiviral RNAi. The optimal molecular glue, VTP‐32, demonstrated potent and pan‐enterovirus (groups A, B, D) antiviral effects.
Yuan Fang   +13 more
wiley   +1 more source

Diagnostic utility of quantitative interferon-gamma release assays in elderly patients with tuberculosis. [PDF]

open access: yesMicrobiol Spectr
Mutoh Y   +14 more
europepmc   +1 more source

Reprogramming Antitumor Immunity: NK Cell Strategies to Navigate the Immunosuppressive Tumor Microenvironment

open access: yesAdvanced Science, EarlyView.
ABSTRACT Tumor immune escape is a major barrier to durable cancer immunotherapy, as advanced malignancies create a tumor microenvironment (TME) that preferentially exhausts and disables T cell responses. While most approved cell therapies are T cell‐based, this limitation motivates the exploration of an alternative effector cell platform.
Tereza Kochs   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy